Interní Med. 2007; 9(2): 70-74

Approach for the antibiotic therapy of respiratory infections

MUDr. Václava Bártů
Pneumologická klinika, Fakultní Thomayerova nemocnice a 1. lékařská fakulta UK, Praha

Upper and low respiratory tract infections belong among the most frequent diseases of childhood and adults and this situation is connected with high prescription and usage of antibiotics. Knowledge of local bacteriological situation of workplace, local drug resistance, national and international recommendations for therapy of respiratory diseases play important role in the choice of the optimal antibiotic drug. The basis requirement for select drug is its efficiency, safety and quality in the clinical practice which leads to the suppression of the bacterial infection. If the bacterial origin of the disease is documented the rational therapy is based on the drug sensitivity tests. Increa­sing use of antibiotics is directly followed by increasing bacterial resistance. Unsubstantiated antibiotic therapy in the bad-founded cases makes the situation wrong and it leads to the decreasing antibiotic efficiency. This strategy increases costs of the effective treatment of respiratory infections. Detailed knowledge of effective spectrum, mechanism of drug penetration into the infection place, local epidemiological situation form the basis presumptions for the optimal antibiotic choice. National and international standards provide the specific recommendations for therapy of respiratory infections.

Keywords: Key words: antibiotics, respiratory infections, clinical efficiency, resistance.

Published: March 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bártů V. Approach for the antibiotic therapy of respiratory infections. Interní Med. 2007;9(2):70-74.
Download citation

References

  1. Amsden GW, Baier IM, Simon S, Treadway G. Efficacy and safety of azithromycin vs levofloxacinin the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Chest 2003; 123: 772-777. Go to original source... Go to PubMed...
  2. Baddour LM, Yu VL, Klugman KP, et al. Combination of antibiotic therapy lowers mortality among severely ill patiens with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170: 440-444. Go to original source... Go to PubMed...
  3. Bébrová E, Beneš J, Čížek J, et al. Doporučený postup pro antibiotickou léčbu komunitních respiračních infekcí v primární péči. Prakt. Lék. 2003; 83: 502-515.
  4. Biederman MS. Clinical significance of macrolide resistence. Eur Respir Rev 2004; 13: 91-95.
  5. Blasi F. The pathogenesis of community-acquired pneumonia. Eur Respir Rev 2004; 13: 60-84.
  6. Brown RB, Iannini P, Gross P, Kukel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia. Chest 2003; 123: 1503-1510. Go to original source... Go to PubMed...
  7. Hirschmann J.V. Antibiotika při běžných infekcích dýchacího ústrojí u dospělých. Jama-CS 2002; 10: 752-758.
  8. Klugman KP. Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections. Eur Respir J 2002; 20 (Suppl. 36): 3s-8s. Go to original source... Go to PubMed...
  9. Kolář M. Antibiotická léčba zánětu plic. Klin Farmakol Farm 2006; 20: 97-99.
  10. Kolek V. Léčba komunitní pneumonie. Medicína po promoci 2004; 5: 46-50.
  11. Kolek V. Komunitní pneumonie. Postgraduální medicína 2006; 6: 630-638.
  12. Kollef MH. Appropriate empirical antibacterial therapy for nosocomial infections. Drug 2003; 63: 2157-2168. Go to original source... Go to PubMed...
  13. Mandell LA. Macrolides and management of community-acquired pneumonia: a review of international guidelines. Eur Respir Rev 2004; 13: 85-87.
  14. Marešová V. Nejčastější chyby a omyly v antibiotické terapii dýchacích cest. Pediatrie pro praxi 2003; 76: 307-311.
  15. Metersky ML, Sweeney TA, Getzow MB, et al. Antibiotic timing and diagnostic uncertainty in medicare patients with pneumonia. Chest 2006; 130: 16-21. Go to original source... Go to PubMed...
  16. Moellering RC Jr. The continuing challenge of respiratory tract infections. Clin Infect Dis 2004; 38: 319-321. Go to original source... Go to PubMed...
  17. Sechser T. Současné možnosti hodnocení účinnosti léčiv v běžné klinické praxi. Čes.-slov.Pediat. 2004; 59: 536-538.
  18. Sechser T, Bečvářová J, Bártů R, et al. Kriteria hodnocení pozitivních listů. Remedia 1997; 7: 145-151.
  19. Singh J, Arrieta AC. O mikrobech a lécích. Průvodce labyrintem antimikrobní terapie infekcí respiračního taktu. Medicína po promoci 2000; 1: 29-35.
  20. Urbášková P. Surveillance antibiotické rezistence. Lékařské listy 2003; 21: 31-33.
  21. Wattanathum A, Chaoprasong CH, Nuthapisud P, et al. Community-acquired pneumonia in southest Asia. Chest 2003; 123: 1512-1519. Go to original source... Go to PubMed...
  22. Wenzel RP, Fowler AA. Acute bronchitis. N Engl J Med 2006; 355: 2125-2130. Go to original source... Go to PubMed...
  23. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult respiratory tract infections. Eur Respir J 2005; 26: 1138-1180. Go to original source... Go to PubMed...
  24. Yu VL, Greenberg RN, Zadeikis A, et al. Levofloxacin efficacy in the treatment of community-acquired legionellosis. Chest 2004; 125: 2135-2139. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.